- Case report
- Open Access
- Open Peer Review
Metastatic cardiac tumor from urothelial carcinoma detected by transthoracic echocardiography: a case report
© Nakashima et al. 2015
- Received: 16 April 2015
- Accepted: 20 October 2015
- Published: 16 November 2015
Cardiac metastasis of urothelial carcinoma is a very rare but clinically important complication. Most cardiac metastases are asymptomatic; symptoms from cardiac metastasis were seen in advanced stage and many of these cases were reported to have a poor prognosis. So it is important to find asymptomatic cardiac metastasis and to start chemotherapy early in order to improve the patient’s prognosis.
A 73-year-old Asian man was referred to our hospital because of a right ventricular tumor. He had a history of left ureteral cancer 9 years ago. In screening echocardiography for paroxysmal atrial fibrillation, a low echogenic tumor was detected in his right ventricular apex, and characteristic ST segment elevation was detected in electrocardiography. An 18F-fluorodeoxyglucose positron emission tomography revealed abnormal uptake in his right ventricular apex tumor and prostate, and a biopsy of the prostatic tumor showed urothelial carcinoma cells. He received systemic gemcitabine, paclitaxel and cisplatin chemotherapy for the urothelial carcinoma, and the cardiac tumor size was reduced temporarily. Finally, he died of multiple organ failure 16 months after his first admission, but his survival period was relatively longer than previous reports.
We experienced a case of a metastatic cardiac tumor from urothelial carcinoma. We found asymptomatic cardiac metastasis by screening echocardiography and electrocardiography. Our patient received systemic chemotherapy and his survival period was relatively longer than previous reports. Electrocardiography and echocardiography may be useful to find asymptomatic cardiac metastasis of neoplasms.
- Cardiac metastasis
- Urothelial carcinoma
Cardiac metastasis from urothelial carcinoma is very uncommon. To the best of our knowledge, only a small number of cases were reported and most of the cases had poor prognosis. We present a case of a metastatic cardiac tumor from urothelial cell carcinoma that was incidentally detected by screening echocardiography. We treated the patient with systemic chemotherapy and succeeded in temporarily reducing the tumor size. The patient had 16 months of survival from diagnosis of cardiac metastasis, which is a longer period than other cases reported in the literature.
A 73-year-old Asian man was referred to our hospital because of a right ventricular tumor. He had a history of left ureteral cancer, and he had undergone nephroureterectomy of his left kidney 9 years ago and transurethral resection of a bladder tumor (TUR-Bt) for intravesical recurrence. After four histories of TUR-Bt, no evidence of cancer recurrence was found for a period of 6 years. However, echocardiography for cardiac screening of paroxysmal atrial fibrillation revealed a low echogenic tumor in his right ventricle (RV), and he was admitted to our hospital for further examination.
We decided to perform systemic chemotherapy for the urothelial carcinoma and cardiac lesion. The patient received gemcitabine, paclitaxel and cisplatin therapy (GTC) for the urothelial carcinoma. After two courses of GTC therapy (75 and 50 % dose), the tumors of the prostate and RV apex wall became smaller, and FDG uptake of the tumors was also reduced as shown by follow-up FDG-PET (Figs. 2c, d and 3b). We suspected the RV tumor to be a metastatic cardiac tumor from urothelial carcinoma without pathological analysis because chemotherapy for the urothelial carcinoma was also effective for the RV tumor.
However, a new pubic bone metastasis was also revealed by follow-up FDG-PET. Radiation therapy was then performed for pubic bone metastasis (3 Gy×18 times, total 54 Gy). After the radiation therapy, chemotherapy was continued but the regime was changed to gemcitabine and cisplatin (GC) because of renal dysfunction. However, after three cycles of GC chemotherapy (50 % dose each), lung metastasis and adrenal gland metastasis were also detected, and chemotherapy itself was discontinued because of renal dysfunction, bone marrow suppression, and poor performance status.
Finally, he died from multiple organ failure 16 months after his first admission. An autopsy was not performed because permission could not be obtained from his family.
According to a recent review, cardiac metastasis from a malignant neoplasm is not rare. In past autopsy studies, the incidences of cardiac metastasis were estimated to range from 1.7 to 14 % in patients with cancer and from 0.7 to 3.5 % in the general population . By contrast, the incidence of primary cardiac malignant neoplasm ranged from only 0.001 to 0.28 % . In addition, the incidence of cardiac metastasis is expected to increase because of the improvement of prognosis for patients with cancer that is associated with advances in cancer therapeutic strategies .
Bussani et al. reported a large series of autopsy cases in 2007 . They examined the cases of 18,751 in-hospital deceased patients, and they found one or more malignant neoplasms in 7289 patients. They also found cardiac metastasis in 662 of the patients (9.1 % of all), and the most common cancers among cardiac metastases were lung cancer (39.2 % of cardiac metastasis cases from lung cancer), breast cancer (10.0 %), mesothelioma (9.4 %) and lymphoma/leukemia (10.0 %). It was also shown that mesothelioma, melanoma and lung cancer have a relatively high potential for cardiac metastasis .
By contrast, cardiac metastasis from urothelial carcinoma is very rare. According to the autopsy study from Bussani et al. only 12 of 307 patients with urothelial carcinoma had cardiac metastasis . In fact, to the best of our knowledge, only a small number of cases of symptomatic cardiac metastasis from urothelial carcinoma have been reported in the English literature. The reason for the rarity of cardiac metastasis from urothelial carcinoma is unclear. However, it may be due to the metastatic pathway of urothelial carcinoma. Malignant tumors metastasize to the heart by four alternative pathways: direct extension, hematogenous spread, lymphatic spread, and intracavitary extension from the inferior vena cava . In epithelial malignancies, including urothelial carcinoma, distal metastasis occurred mainly by the lymphatic pathway . However, in the heart, lymphatic flow is directly from the endocardium to the epicardium, and lymphatics drain from the heart to the mediastinum. It is therefore speculated that tumor cells cannot easily reach the heart without lymphatic flow stagnating due to tumor emboli . This mechanism of the lymphatic system may play an important role in the rarity of cardiac metastasis from urothelial carcinoma.
The prognosis of cardiac metastasis from urothelial carcinoma is poor. Hattori et al. showed in a review of 14 cases that most patients died shortly after the original diagnosis or first visit . Systemic chemotherapy or surgical resection of the tumor resulted in a prognosis of relatively long survival in only a few patients [5–8]. In our case, cardiac metastasis was detected by screening echocardiography for paroxysmal atrial fibrillation before the patient had any complaint, and systemic chemotherapy for urothelial carcinoma resulted in relatively long survival. Thus, early detection of cardiac metastasis and prostatic recurrence of carcinoma may have been important for the relatively long survival of our patient.
In addition, in our case, ECG showed characteristic abnormality (mild ST elevation and T inversion in V1–3). The exact cause of this ECG abnormality is unknown, but myocardial injury of the RV apex wall attributed to the metastatic tumor may have resulted in the ECG abnormality. A similar ECG abnormality was reported by Na et al. in a case of mimicking ST-segment elevation in myocardial infarction . This case suggested that new onset ECG abnormality might provide a clue for the diagnosis of cardiac metastasis.
We experienced a case of a metastatic cardiac tumor from urothelial carcinoma. He received systemic chemotherapy and his survival period was relatively longer than previous reports. In metastasis to the heart, most patients are asymptomatic, and it is therefore important to detect ECG or echocardiographical abnormality, recognize cardiac metastasis, and start appropriate treatment as early as possible.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
All authors have no disclosures in preparation of this manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Al-Mamgani A, Baartman L, Baaijens M, de Pree I, Incrocci L, Levendag PC. Cardiac metastases. Int J Clin Oncol. 2008;13:369–72.View ArticlePubMedGoogle Scholar
- Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastases. J Clin Pathol. 2007;60:27–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Burke A, Virmani R. Tumors of the heart and great vessels. Atlas of tumor pathology. 3rd ed. Washington DC: Armed forces institute of pathology; 1996. p. 195–209.Google Scholar
- Hattori S, Miyajima A, Maeda T, Takeda T, Morita S, Kosaka T, et al. Metastatic urothelial carcinoma to pericardia manifested by dyspnea from cardiac tamponade during systemic chemotherapy: case report and literature review. Can Urol Assoc J. 2012;6:E184–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Doshi TV, Doshi JV, Makaryus JN, Makaryus AN. A rare case of successfully treated cardiac metastasis from transitional cell bladder cancer. Am J Ther. 2013;20:307–10.PubMedGoogle Scholar
- Shields AM, Pomplun S, Deshpande R, Whitaker DC. Right ventricular metastasis of transitional cell carcinoma of the renal pelvis: successful single stage surgical treatment. Interact Cardiovasc Thorac Surg. 2011;12:297–300.View ArticlePubMedGoogle Scholar
- Spiliotopoulos K, Argiriou M, Argyrakos T, Haritopoulos K, Kanakakis K, Sakellaridis T, et al. Solitary metastasis of urothelial carcinoma of the urinary bladder to the heart: an unusual clinical manifestation. J Trorac Cardiovasc Surg. 2008;136:1377–8.View ArticleGoogle Scholar
- Mountzios G, Bamias A, Dalianis A, Danias P, Pantelidaki E, Nanas J, et al. Endocardial metastases as the only site of relapse in a patient with bladder carcinoma: a case report and review of the literature. Int J Cardial. 2010;140:e4–7.View ArticleGoogle Scholar
- Na JO, Choi CU, Lim HE. Cardiac metastasis of bladder cancer presented as mimicking ST segment elevation myocardial infarction. Eur Heart J. 2011;32:40.View ArticlePubMedGoogle Scholar